



UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE

United States Patent and Trademark Office

Address: COMMISSIONER FOR PATENTS

P.O. Box 1450

Alexandria, Virginia 22313-1450

www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
10/536,782	11/23/2005	Jose Esteve-Soler	785-012246-US (PAR)	4290
2512 PERMAN & GREEN 425 POST ROAD FAIRFIELD, CT 06824	7590 12/12/2008		<div>EXAMINER</div> <div>RAMACHANDRAN, UMAMAHESWARI</div>	
			<div>ART UNIT</div> <div>1617</div>	<div>PAPER NUMBER</div>
			<div>MAIL DATE</div> <div>12/12/2008</div>	<div>DELIVERY MODE</div> <div>PAPER</div>

Please find below and/or attached an Office communication concerning this application or proceeding.

The time period for reply, if any, is set in the attached communication.

Office Action Summary

Application No.

10/536,782

Applicant(s)

ESTEVE-SOLER ET AL.

ExaminerUMAMAHESWARI
RAMACHANDRAN**Art Unit**

1617

-- The MAILING DATE of this communication appears on the cover sheet with the correspondence address --
Period for Reply

A SHORTENED STATUTORY PERIOD FOR REPLY IS SET TO EXPIRE 1 MONTH(S) OR THIRTY (30) DAYS, WHICHEVER IS LONGER, FROM THE MAILING DATE OF THIS COMMUNICATION.

- Extensions of time may be available under the provisions of 37 CFR 1.136(a). In no event, however, may a reply be timely filed after SIX (6) MONTHS from the mailing date of this communication.
- If NO period for reply is specified above, the maximum statutory period will apply and will expire SIX (6) MONTHS from the mailing date of this communication.
- Failure to reply within the set or extended period for reply will, by statute, cause the application to become ABANDONED (35 U.S.C. § 133). Any reply received by the Office later than three months after the mailing date of this communication, even if timely filed, may reduce any earned patent term adjustment. See 37 CFR 1.704(b).

Status

- 1) ☒ Responsive to communication(s) filed on 26 May 2005.
- 2a) ☐ This action is **FINAL**. 2b) ☐ This action is non-final.
- 3) ☐ Since this application is in condition for allowance except for formal matters, prosecution as to the merits is closed in accordance with the practice under *Ex parte Quayle*, 1935 C.D. 11, 453 O.G. 213.

Disposition of Claims

- 4) ☒ Claim(s) 1-25 is/are pending in the application.
- 4a) Of the above claim(s) _____ is/are withdrawn from consideration.
- 5) ☐ Claim(s) _____ is/are allowed.
- 6) ☐ Claim(s) _____ is/are rejected.
- 7) ☐ Claim(s) _____ is/are objected to.
- 8) ☒ Claim(s) 1-25 are subject to restriction and/or election requirement.

Application Papers

- 9) ☐ The specification is objected to by the Examiner.
- 10) ☐ The drawing(s) filed on _____ is/are: a) ☐ accepted or b) ☐ objected to by the Examiner.
Applicant may not request that any objection to the drawing(s) be held in abeyance. See 37 CFR 1.85(a).
Replacement drawing sheet(s) including the correction is required if the drawing(s) is objected to. See 37 CFR 1.121(d).
- 11) ☐ The oath or declaration is objected to by the Examiner. Note the attached Office Action or form PTO-152.

Priority under 35 U.S.C. § 119

- 12) ☐ Acknowledgment is made of a claim for foreign priority under 35 U.S.C. § 119(a)-(d) or (f).
- a) ☐ All b) ☐ Some * c) ☐ None of:
- ☐ Certified copies of the priority documents have been received.
 - ☐ Certified copies of the priority documents have been received in Application No. _____.
 - ☐ Copies of the certified copies of the priority documents have been received in this National Stage application from the International Bureau (PCT Rule 17.2(a)).

* See the attached detailed Office action for a list of the certified copies not received.

Attachment(s)

- ☐ Notice of References Cited (PTO-892)
- ☐ Notice of Draftperson's Patent Drawing Review (PTO-948)
- ☐ Information Disclosure Statement(s) (PTO/SB/08)
Paper No(s)/Mail Date _____
- ☐ Interview Summary (PTO-413)
Paper No(s)/Mail Date _____
- ☐ Notice of Informal Patent Application
- ☐ Other: _____

DETAILED ACTION

Claims 1-25 are pending.

Lack of Unity

Restriction is required under 35 U.S.C. 121 and 372.

This application contains the following inventions or groups of inventions, which are not so linked as to form a single general inventive concept under PCT Rule 13.1.

In accordance with 37 CFR 1.499, applicant is required, in reply to this action, to elect a single invention to which the claims must be restricted.

Group I, claims 1-7, 14 and 15 are drawn to prophylaxis and/or treatment of disorders based on an impairment of nitric oxide (NO) production and/or impairment of regulation of EDHF function using a compound of formula I (claim 1).

Group II, claims 1-6, 8, 12, 13 are drawn to the prophylaxis and/or treatment of microcirculation disorders using a compound of formula I (claim 1).

Group III, claims 1-6, 9 are drawn to the prophylaxis and/or treatment of retinopathy using a compound of formula I (claim 1).

Group IV, claims 1-6, 10 are drawn to the prophylaxis and/or treatment of sexual dysfunction, preferably erectile dysfunction using a compound of formula I (claim 1).

Group V, claims 1-6, 11 are drawn to the prophylaxis and/or treatment of renal disorders using a compound of formula I (claim 1).


Group VI, claims 1-4, 14-25 are drawn to a medicament formulation comprising a compound of formula I (claim 1).

The inventions listed as Groups I – VI do not relate to a single general inventive concept under PCT Rule 13.1 because, under PCT Rule 13.2, they lack the same or corresponding technical features.

An international application should relate to only one invention or, if there is more than one invention, the inclusion of those inventions in one international application is only permitted if all inventions are so linked as to form a single general inventive concept (PCT Rule 13.1). With respect to a group of inventions claimed in an international application, unity of invention exists only when there is a technical relationship among the claimed inventions involving one or more of the same or corresponding special technical features.

The expression "special technical features" is defined in PCT Rule 13.2 as meaning those technical features that define a contribution which each of the inventions, considered as a whole, makes over the prior art. The determination is made on the contents of the claims as interpreted in light of the description and drawings (if any). Whether or not any particular technical feature makes a "contribution" over the prior art, and therefore constitutes a "special technical feature", should be considered with respect to novelty and inventive step.

The common technical feature in all the groups is a compound of formula given below. This element cannot be a special technical feature under PCT Rule 13.2 because the element is shown in the prior art.



Courten et al. (U.S. 4,513,117) teaches calcium dobesilate, a compound of the above said formula to be useful in coronary heart diseases, myocardial infarction etc. (see Abstract). As a result, no special technical features exist among the different groups because the inventions in Groups I-VI fail to make a contribution over the prior art with respect to novelty or inventive step. In conclusion, there is lack of unity of inventions, and therefore restriction for examination purposes as indicated is proper.

If Applicant elects Group I applicant is further required to elect a single disclosed species of the compound (example, calcium dobesilate), and a species of the disorder based on an impairment of nitric oxide (NO) production and/or impairment of regulation of EDHF function.

If Applicant elects Group II applicant is further required to elect a single disclosed species of the compound (example, calcium dobesilate), and a single disclosed species of the microcirculation disorders, example coronary microcirculation disorder.

If Applicant elects Group III applicant is further required to elect a single disclosed species of the compound (example, calcium dobesilate).

If Applicant elects Group IV applicant is further required to elect a single disclosed species of the compound (example, calcium dobesilate), and a single disclosed species of the sexual dysfunction disorder such as erectile dysfunction.

If Applicant elects Group V applicant is further required to elect a single disclosed species of the compound (example, calcium dobesilate), and a single disclosed species of the renal disorder such as a kidney disorder, renal acidosis.

If Applicant elects Group VI applicant is further required to elect a single disclosed species of the compound (example, calcium dobesilate), and a single disclosed species of the water insoluble polymer (e.g. alkyl cellulose) and a wax (carnauba wax).

Applicant is required, in reply to this action, to elect a single species to which the claims shall be restricted if no generic claim is finally held to be allowable. The reply must also identify the claims readable on the elected species, including any claims subsequently added. An argument that a claim is allowable or that all claims are generic is considered non-responsive unless accompanied by an election.

Applicant is reminded that upon the cancellation of claims to a non-elected invention, the inventorship must be amended in compliance with 37 CFR 1.48(b) if one or more of the currently named inventors is no longer an inventor of at least one claim remaining in the application. Any amendment of inventorship must be accompanied by a request under 37 CFR 1.48(b) and by the fee required under 37 CFR 1.17(i). Applicant is advised that the reply to this requirement to be complete must include an election of the invention to be examined even though the requirement be traversed (37 CFR 1.1.43).

The election of an invention may be made with or without traverse. To reserve a right to petition, the election must be made with traverse. If the reply does not distinctly

and specifically point out supposed errors in the restriction requirement, the election shall be treated as an election without traverse.

Because the restriction/election requirement is complex, a telephone call to applicant's agent to request an oral election was not made. See MPEP § 812.01.

Conclusion

Any inquiry concerning this communication or earlier communications from the examiner should be directed to Umamaheswari Ramachandran whose telephone number is 571-272-9926. The examiner can normally be reached on M-F 8:30 AM - 5:00 PM.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Sreeni Padmanabhan can be reached on 571-272-0629. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300.

Information regarding the status of an application may be obtained from the Patent Application Information Retrieval (PAIR) system. Status information for published applications may be obtained from either Private PAIR or Public PAIR. Status information for unpublished applications is available through Private PAIR only. For more information about the PAIR system, see <http://pair-direct.uspto.gov>. Should you have questions on access to the Private PAIR system, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative or access to the automated information system, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000.

Application/Control Number: 10/536,782
Art Unit: 1617

Page 7

/SREENI PADMANABHAN/

Supervisory Patent Examiner, Art Unit 1617